Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Operating Leases (2019 - 2025)

Historic Operating Leases for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $50.0 million.

  • Avidity Biosciences' Operating Leases rose 121593.36% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year increase of 121593.36%. This contributed to the annual value of $3.0 million for FY2024, which is 5240.62% down from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Operating Leases is $50.0 million, which was up 121593.36% from $1.2 million recorded in Q2 2025.
  • Avidity Biosciences' Operating Leases' 5-year high stood at $50.0 million during Q3 2025, with a 5-year trough of $877000.0 in Q3 2021.
  • Moreover, its 5-year median value for Operating Leases was $6.2 million (2023), whereas its average is $7.5 million.
  • Data for Avidity Biosciences' Operating Leases shows a peak YoY increase of 121593.36% (in 2025) and a maximum YoY decrease of 7379.25% (in 2025) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Operating Leases (Quarter) stood at $10.0 million in 2021, then fell by 23.88% to $7.6 million in 2022, then dropped by 18.06% to $6.2 million in 2023, then plummeted by 52.41% to $3.0 million in 2024, then skyrocketed by 1589.75% to $50.0 million in 2025.
  • Its last three reported values are $50.0 million in Q3 2025, $1.2 million for Q2 2025, and $2.1 million during Q1 2025.